RANK/RANKL Axis in Melanoma

Melanoma is considered to be one of the most aggressive forms of skin neoplasms. Despite aggressive researches towards finding treatments, no effective therapy exists to inhibit the metastatic spread of malignant melanoma. The 5-year survival rate of metastatic melanoma is still significantly low, and there has been an earnest need to develop more effective therapies with greater anti-melanoma activity. Through the accomplishment of over 100 distinguished and respected researchers from 19 different countries, this book covers a wide range of aspects from various standpoints and issues related to melanoma. These include the biology of melanoma, pigmentations, pathways, receptors and diagnosis, and the latest treatments and therapies to make potential new therapies. Not only will this be beneficial for readers, but it will also contribute to scientists making further breakthroughs in melanoma research.

[1]  J. Penninger,et al.  Receptor activator of NF-κB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit , 2011, Proceedings of the National Academy of Sciences.

[2]  A. Haeseler,et al.  Central control of fever and female body temperature by RANKL/RANK , 2009, Nature.

[3]  B. Pitard,et al.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma , 2010 .

[4]  M. Mikkola.  TNF superfamily in skin appendage development. , 2008, Cytokine & growth factor reviews.

[5]  D. Heymann,et al.  Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. , 2007, Oncology reports.

[6]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[7]  J. Penninger,et al.  RANK signals from CD4+3− inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla , 2007, The Journal of Experimental Medicine.

[8]  B. Le Goff,et al.  DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.

[9]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[10]  M. Dimopoulos,et al.  Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton , 2007, Acta oncologica.

[11]  M. Padrines,et al.  OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. , 2006, Bone.

[12]  A. Potti,et al.  Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation , 2006, Cancer.

[13]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[14]  B. Abrahamsen,et al.  Technology evaluation: denosumab, Amgen. , 2005, Current opinion in molecular therapeutics.

[15]  E. Schwarz,et al.  The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[16]  R. Vessella,et al.  Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.

[17]  M. Padrines,et al.  Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. , 2005, Drug discovery today.

[18]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[19]  A. Ohazama,et al.  Opg, Rank, and Rankl in Tooth Development: Co-ordination of Odontogenesis and Osteogenesis , 2004, Journal of dental research.

[20]  W. Dougall,et al.  Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.

[21]  D. Goltzman.  Osteolysis and cancer. , 2001, The Journal of clinical investigation.

[22]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[23]  R. Vessella,et al.  Osteoprotegerin and rank ligand expression in prostate cancer. , 2001, Urology.

[24]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[25]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[26]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[27]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[28]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[29]  J. Penninger,et al.  Novel functions of RANK(L) signaling in the immune system. , 2010, Advances in experimental medicine and biology.

[30]  C. Brisken,et al.  What signals operate in the mammary niche? , 2008, Breast disease.

[31]  W. Dougall,et al.  RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes , 2008, The Prostate.

[32]  P. Kostenuik,et al.  Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis , 2007, Clinical & Experimental Metastasis.

[33]  D. Heymann,et al.  RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. , 2006, International journal of oncology.